Lv72
5000 积分 2023-08-09 加入
Discovery of the Novel, Orally Active, and Selective LPA1 Receptor Antagonist ACT-1016-0707 as a Preclinical Candidate for the Treatment of Fibrotic Diseases
25天前
已完结
Discovery of an Oxycyclohexyl Acid Lysophosphatidic Acid Receptor 1 (LPA1) Antagonist BMS-986278 for the Treatment of Pulmonary Fibrotic Diseases
25天前
已完结
Discovery of GS-2278, a Potent and Selective LPAR1 Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis
25天前
已完结
Lead generation from N-[benzyl(4-phenylbutyl)carbamoyl]amino acid as a novel LPA1 antagonist for the treatment of systemic sclerosis
26天前
已完结
Mechanism of hepatobiliary toxicity of the LPA1 antagonist BMS-986020 developed to treat idiopathic pulmonary fibrosis: Contrasts with BMS-986234 and BMS-986278
26天前
已完结
Idiopathic pulmonary fibrosis
27天前
已完结
Lysophosphatidic Acid (LPA) Induces a Cell Growth Response by Lung Cancer Cells through the Involvement of LPA Receptors
1个月前
已完结
The novel lysophosphatidic acid receptor 1-selective antagonist, ACT-1016-0707, has unique binding properties that translate into effective anti-fibrotic and anti-inflammatory activity in different models of pulmonary fibrosis
1个月前
已完结
Neutral LPAR1 Antagonists for the Treatment of Idiopathic Pulmonary Fibrosis
1个月前
已完结
Discovery of GS-2278, a Potent and Selective LPAR1 Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis
1个月前
已完结
皖公网安备34019202002308
